Maria J. Monte

Salamanca, CL, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 57 publications

Secreted chimeric proteins as a strategy to correct SOX17 deficiency and attenuate the malignant phenotype of cholangiocarcinoma cells: a proof-of-concept study.

Secreted chimeric proteins as a strategy to correct SOX17 deficiency and attenuate the malignant phenotype of cholangiocarcinoma cells: a proof-of-concept study.

Journal: Acta pharmacologica Sinica

Published: December 19, 2025

Usefulness of plasma bile acid profile as a prognostic biomarker for drug-induced liver injury.

Usefulness of plasma bile acid profile as a prognostic biomarker for drug-induced liver injury.

Journal: EBioMedicine

Published: October 25, 2025

Screening for Mutations Causing ACOX2 Deficiency-associated Hypertransaminasemia in Patients with Cryptogenic Liver Injury.

Screening for Mutations Causing ACOX2 Deficiency-associated Hypertransaminasemia in Patients with Cryptogenic Liver Injury.

Journal: Journal of clinical and translational hepatology

Published: July 07, 2025

Bile acids in liver and gastrointestinal cancer.

Bile acids in liver and gastrointestinal cancer.

Journal: Seminars in cancer biology

Published: April 19, 2025

Gut-to-bile transfer of microbially amidated minor bile acids in patients with hepatopancreatobiliary disorders.

Gut-to-bile transfer of microbially amidated minor bile acids in patients with hepatopancreatobiliary disorders.

Journal: Hepatology (Baltimore, Md.)

Published: March 27, 2025

A novel noninvasive test based on near-infrared fluorescent cholephilic probes for hepatobiliary secretory function assessment.

A novel noninvasive test based on near-infrared fluorescent cholephilic probes for hepatobiliary secretory function assessment.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: November 22, 2024

Stard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity.

Stard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity.

Journal: Hepatology (Baltimore, Md.)

Published: July 16, 2024

Synthesis, Characterization, and Potential Usefulness in Liver Function Assessment of Novel Bile Acid Derivatives with Near-Infrared Fluorescence (NIRBAD).

Synthesis, Characterization, and Potential Usefulness in Liver Function Assessment of Novel Bile Acid Derivatives with Near-Infrared Fluorescence (NIRBAD).

Journal: Bioconjugate chemistry

Published: July 03, 2024

Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD).

Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD).

Journal: Clinical science (London, England : 1979)

Published: June 17, 2024

Identification of Neuritin 1 as a local metabolic regulator of brown adipose tissue.

Identification of Neuritin 1 as a local metabolic regulator of brown adipose tissue.

Journal: Nature communications

Published: March 20, 2024

Impact of liver diseases and pharmacological interactions on the transportome involved in hepatic drug disposition.

Impact of liver diseases and pharmacological interactions on the transportome involved in hepatic drug disposition.

Journal: Biochemical pharmacology

Published: January 18, 2024

New insights into the regulation of bile acids synthesis during the early stages of liver regeneration: A human and experimental study.

New insights into the regulation of bile acids synthesis during the early stages of liver regeneration: A human and experimental study.

Journal: Biochimica et biophysica acta. Molecular basis of disease

Published: November 16, 2023

Showing 1-12 of 57

Last Updated: 09/26/2026